NAD+ Reference

Plain English

What it is

NAD+ (nicotinamide adenine dinucleotide) is a natural molecule every cell uses to turn food into energy. The injectable form sold by IV-drip clinics and research-chemical sellers is not an FDA-approved drug. It is mixed by hand (compounded), so quality varies by source, and it is different from the oral NMN and NR products, which are listed separately.

What people use it for

People get NAD+ drips hoping for more energy, less brain fog, anti-aging effects, addiction-recovery support, and relief from long-lasting tiredness. It is not approved for any of these uses, and the marketing runs well ahead of the human evidence.

What the science shows

NAD+ levels shift as the body ages, and in animal studies raising NAD+ improves how cells make energy and several signs of aging. But human proof for the injected form is thin and limited to small, early studies, with no large trial backing the popular claims. Most of the stronger human data is on the oral NMN and NR precursors rather than on injected NAD+ itself.

The catch

NAD+ infusions commonly cause uncomfortable reactions during the drip, such as cramping, nausea, a racing heart, and chest pressure, which is why clinics often run the drip more slowly. Because it is compounded instead of FDA-approved, its purity and safety are not guaranteed.

Reference summary

Cellular NAD+ levels decline with age, and animal models show that restoring NAD+ improves mitochondrial function and several aging biomarkers (Verdin 2015 Science review; Rajman 2018 Cell Metabolism in-vivo NAD-boosting review). Human evidence for the INJECTABLE NAD+ at the indications people use it for (longevity, addiction recovery, chronic fatigue, post-viral fatigue) is limited to small open-label series and a handful of registered ClinicalTrials.gov studies; no large outcome trial supports those indications. Most positive human pharmacokinetic data is on the oral precursors NMN and NR rather than on injectable NAD+ itself.

Regulatory and posture

Categories

Nootropic, Longevity, Metabolic

Aliases

Nicotinamide adenine dinucleotide, NAD, NAD+ infusion, NAD+ injection, IV NAD, SubQ NAD+

Evidence posture

translational - Mechanism and animal data are real; human evidence for injectable NAD+ at the community-cited indications is sparse. Compounded preparations are not FDA-approved and quality varies by source. Infusion-rate side effects (chest pressure, flushing, anxiety, nausea) are widely reported and clinics typically slow the drip to manage them.

Regulatory status

No FDA-approved injectable NAD+ drug label exists. The intravenous and subcutaneous NAD+ marketed by IV-therapy clinics and research-chemical sellers is compounded; the FDA has not approved any NAD+ product for anti-aging, addiction recovery, neurodegenerative disease, chronic fatigue, or any other community-cited indication. Distinct from the oral NAD+ precursors NMN and NR catalogued separately.

Content review status

research reference

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• Injection-site rotation overview - Public overview of the Pro site-rotation planner.